title: Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma.
abstract: Gliosarcoma is a very rare primary neoplasm of the central nervous system classified as a variant of glioblastoma. Cortactin, fascin and survivin have been found in several human cancers to play important roles in tumor progression, but the expression pattern of these biomarkers in gliosarcoma is unclear. Immunostaining for cortactin, fascin and survivin was assessed in 6 surgical specimens of brain gliosarcoma, and the relationship between the expression of these biomarkers and tumor size or clinical parameters were examined. Five of our six patients with gliosarcoma survived 3-17 months. One patient is still alive for more than 24 months. The mean immunostaining scores for cortactin were significantly higher in the gliomatous (score 236.6 +/- 45.4) and sarcomatous (score 233.3 +/- 51.4) components than in normal brain tissues (score 21.6 +/- 6.6). The mean cytoplasmic immunostaining scores for fascin and survivin were also significantly higher in the gliomatous and sarcomatous components than in normal brain tissues. In addition, survivin was also stained in the nucleus of tumor cells. Linear regression analysis showed that fascin score in the gliomatous component was significantly associated with tumor size (R = 0.69) and the fascin score in the sarcomatous component was significantly associated with patient's age (R = 0.87). In addition, the survivin cytoplasmic scores in the gliomatous and sarcomatous components were inversely associated with tumor size. Our results demonstrated that over-expression of cortactin, fascin and survivin is associated with malignant transformation of brain gliosarcoma. Development of drugs that target cortactin, fascin and survivin expression may be therapeutic to patients with gliosarcoma.
authors.affiliation: Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.
authors.forename: Jia-Hong
authors.initials: JH
authors.lastname: Chen
authors.forename: Kuan-Yu
authors.initials: KY
authors.lastname: Chen
authors.forename: Hsin-I
authors.initials: HI
authors.lastname: Ma
authors.forename: Cheng-Ping
authors.initials: CP
authors.lastname: Yu
authors.forename: Shin
authors.initials: S
authors.lastname: Nieh
authors.forename: Herng-Sheng
authors.initials: HS
authors.lastname: Lee
authors.forename: Jong-Shiaw
authors.initials: JS
authors.lastname: Jin
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D002352:Carrier Proteins / Q000032:analysis*; D051356:Cortactin / Q000032:analysis*; D005260:Female; D018316:Gliosarcoma / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis*; D008297:Male; D008840:Microfilament Proteins / Q000032:analysis*; D008875:Middle Aged; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D002352:Carrier Proteins; D051356:Cortactin; D051034:Inhibitor of Apoptosis Proteins; D008840:Microfilament Proteins; D000077022:Survivin; C020324:fascin